Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07461532 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 20, 2026 to Sep 30, 2027v4 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment reduced: 40 → 20 participants
    • Start date: Feb 4, 2026 to Apr 1, 2026
    • Study completion pushed from Aug 1, 2027 to Sep 30, 2027
    • Eligibility criteria expanded, about 53 words
    • Secondary endpoints: 2 to 1
    • Study description shortened, about 84 words
  2. Re-verified, no change to tracked fieldsv3
  3. Start date: Mar 4, 2025 to Feb 4, 2026v2 Show 10 more changesShow less
    • Primary endpoints: 1 to 2
    • Trial status: Completed to Recruiting
    • Primary completion date: Mar 1, 2026 to Mar 20, 2026
    • Study completion date: Mar 1, 2026 to Aug 1, 2027
    • Interventions: Apixaban 2.5 MG (Drug), subcutaneous Low Molecular Weight Heparin (Drug) to Apixaban 2.5 MG (Drug)
    • Eligibility criteria expanded, about 52 words
    • Secondary endpoints revised (2)
    • Study description shortened, about 35 words
    • Site details revised
    • Study title shortened, about 3 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Trial Details
NCT Number NCT07461532
Lead Sponsor Northern Jiangsu People's Hospital
Conditions
(from sponsor)		 Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
Related terms Fibrosis, Hypersplenism, Hypertension, Portal
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov